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Correction to: British Journal of Cancer (2011) 104, 781–789.
doi:10.1038/bjc.2011.10
Since publication of this paper in February 2011, the authors
have been made aware of an error in the name of the plant species
used in their study. The plant name should be corrected to:
Hemsleya amabilis Diels (incorrect spelling in paper: Hemsleya
amalils Diels).
In addition, the chemical structure of Cuc IIa was incorrectly
expressed (shown in Figure 1A in the original publication).
Figure 1A is now corrected and shown, below.
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Figure 1 Cuc IIa suppresses cancer cell expansion. (A) Chemical
structure of Cuc IIa.
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